Zoetis (ZTS) Retained Earnings (2012 - 2026)
Zoetis' (ZTS) quarterly Retained Earnings came in at $1.1 billion in Q1 2026, up 208.65% year-on-year from $358.0 million in Q1 2025, and up 237.44% on a QoQ basis from -$804.0 million in Q4 2025.
Zoetis (ZTS) Retained Earnings (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Retained Earnings data on file, last reported at $1.1 billion in Q1 2026.
- On a quarterly basis, Retained Earnings rose 208.65% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 208.65% increase from a year earlier, with the FY2025 full-year figure at -$804.0 million, down 106.72% from the prior year.
- Retained Earnings for Q1 2026 stood at $1.1 billion, up from -$804.0 million in the prior quarter.
- Over the last five years, Retained Earnings for ZTS reached as high as $12.0 billion in Q4 2024 and fell as low as -$1.0 billion in Q1 2025.
- Historically, Retained Earnings has averaged $1.7 billion across 5 years, with a median of -$804.0 million in 2025.
- Across the five-year window, Retained Earnings sank 5452.94% in 2022 and jumped 1550.37% in 2024, its largest moves.
- Year by year, Retained Earnings stood at -$944.0 million in 2022, then increased by 11.12% to -$839.0 million in 2023, then jumped by 1526.46% to $12.0 billion in 2024, then tumbled by 106.72% to -$804.0 million in 2025, then surged by 237.44% to $1.1 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $1.1 billion in Q1 2026, -$804.0 million in Q4 2025, and $1.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | -804.00 Mn |
| Sep 30, 2025 | 1.22 Bn |
| Jun 30, 2025 | -877.00 Mn |
| Mar 31, 2025 | -1.02 Bn |
| Dec 31, 2024 | 11.97 Bn |
| Sep 30, 2024 | 11.81 Bn |
| Jun 30, 2024 | -845.00 Mn |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | -839.00 Mn |
| Sep 30, 2023 | -814.00 Mn |
| Jun 30, 2023 | -895.00 Mn |
| Mar 31, 2023 | 1.08 Bn |
| Dec 31, 2022 | -944.00 Mn |
| Sep 30, 2022 | -809.00 Mn |
| Jun 30, 2022 | 1.06 Bn |
| Mar 31, 2022 | 7.63 Bn |
| Dec 31, 2021 | -17.00 Mn |
| Sep 30, 2021 | -667.00 Mn |
| Jun 30, 2021 | -623.00 Mn |